Om

Azora Therapeutics, Inc. is a biopharmaceutical company developing small-molecule therapies for serious inflammatory and autoimmune diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist being developed for ulcerative colitis. The compound is designed to activate therapeutic pathways locally in the colon while limiting systemic exposure, reflecting the company’s focus on targeted treatment approaches for gastrointestinal inflammation. Azora’s research platform centers on proprietary aryl hydrocarbon receptor agonists, with potential applications across gastroenterology and other inflammatory disease areas. The company also maintains a focus on dermatology-related indications within the broader autoimmune and inflammatory disease market. Through drug discovery and clinical development, Azora Therapeutics, Inc. participates in the biopharmaceutical sector serving patients with chronic inflammatory conditions and addressing demand for orally administered, mechanism-based therapies. Its activities are centered on advancing proprietary drug candidates rather than marketing an established portfolio of commercial medicines.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I AZORA THERAPEUTICS MED ENDAVU: Køb Azora Therapeutics ($AZR) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Azora Therapeutics, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.